Skip to content

Clinical Relevance of Thoracic Echography for the Early Diagnosis of Interstitial Lung Disease in Systemic Scleroderma - Pilot Study

Pertinence Clinique de l'échographie Thoracique Pour le Diagnostic précoce de la Pneumopathie Interstitielle Diffuse de la sclérodermie systémique - Etude Pilote

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04725786
Acronym
PRECOSS
Enrollment
30
Registered
2021-01-27
Start date
2021-03-17
Completion date
2022-06-08
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Sclerosis

Brief summary

Diffuse interstitial lung disease (PID) is the leading cause of death in systemic scleroderma (SSc). Major progress has recently been made in its therapeutic management. Early diagnosis is essential to optimize this management. Current diagnostic techniques are based on high-resolution computed tomography on the thorax (HRCT) and pulmonary functional tests (PFT). However, these explorations have their limitations. Thus, there is a need for new techniques for a very early diagnosis of PID-SSc. Thoracic ultrasound (TUS) is an innovative, easily accessible, non-irradiating, inexpensive and painless tool. It is an emerging technique for the diagnosis of PID and has already proven its sensitivity for the detection of interstitial damage, as defined by HRCT. The main objective of the PRECOSS study is to describe the prevalence of an ultrasound interstitial syndrome in patients with SSc, free of PID-SSc (defined by the Goh criteria) detectable by HRCT.

Interventions

OTHERthoracic echography

The research intervention corresponds to the performance of a thoracic echography to diagnose an incipient pulmonary interstitial syndrome.

Sponsors

University Hospital, Tours
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years old * Diagnosis of systemic scleroderma according to EULAR/ACR 2013 criteria * Absence of diffuse interstitial lung disease proven by scanner on the day of inclusion * Forced vital capacity ≥ 80% of the value predicted on the last respiratory function test performed. * Carbon monoxide diffusion capacity corrected for hemoglobinemia ≥ 70% of the value predicted on the last respiratory function test performed. * Patient capable of performing functional exploration during the year * Affiliation to a social security system * Patient who has given free and informed consent

Exclusion criteria

* Any other connectivity associated to systemic sleroderma * Any chronic pathologies, co-morbidities, history judged by the investigator as being likely to lead to complications for the patient and/or which may impact the results of functional exploration during exercise. * All known fibrotic and/or obstructive respiratory pathologies. * Presence of echocardiographic signs of pulmonary arterial hypertension according to 2015 criteria * Diagnosis of left heart disease * Cumulative smoking \> 10 packs.years * Infectious pneumonia within 90 days prior to inclusion * Acute respiratory illness requiring hospitalization within one year prior to inclusion * Pregnant or breastfeeding woman * Refusal to participate in the study * Refusal to use the data * Adults under legal protection (temporary protection measure, curatorship, guardianship)

Design outcomes

Primary

MeasureTime frameDescription
Presence of interstitial syndrome on echographyAt baselineInterstitial syndrome is defined by the total number of B lines is greather than or equal to 10 and/or the average thickness of the pleural line is greater than 3 mm on at least one test site and/or the irregularity score of the pleural line is greater than 16%

Secondary

MeasureTime frameDescription
CoughAt baselineEvaluation by Leicester Cough Questionnaire - French translation
Ventilatory mechanicsAt BaselineMeasured by spirometry
Assessment of Quality of lifeAt baselineAssessed by Cochin 17-item Scleroderma Functional Scale
Exercise capacityAt baselineMeasured by cardiopulmonary exercise testing
Circulatory responseAt baselineMeasured by cardiopulmonary exercise testing
DyspnoeaAt baselineMeasured by cardiopulmonary exercise testing
Pulmonary gas exchangeAt BaselineMeasured by cardiopulmonary exercise testing

Other

MeasureTime frameDescription
Nailfold capillaroscopyAt baselineClassification of Cutulo

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026